» Articles » PMID: 23839973

Myelin Inhibits Oligodendroglial Maturation and Regulates Oligodendrocytic Transcription Factor Expression

Overview
Journal Glia
Specialty Neurology
Date 2013 Jul 11
PMID 23839973
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Myelin loss is a hallmark of multiple sclerosis (MS) and promoting central nervous system myelin repair has become a major therapeutic target. Despite the presence of oligodendrocytes precursors cells (OPCs) in chronic lesions of MS, remyelination often fails. The mechanism underlying this failure of remyelination remains unknown, but it is hypothesized that environmental cues act to inhibit the maturation/differentiation of oligodendroglia, preventing remyelination. The rate of CNS remyelination is correlated to the speed of phagocytosis of myelin debris, which is present following demyelination and trauma. Thus, myelin debris could inhibit CNS remyelination. Here, we demonstrate that OPCs cultured on myelin were robustly inhibited in their maturation, as characterized by the decreased expression of immature and mature oligodendrocytes markers, the impaired production of myelin gene products, as well as their stalled morphological complexity relative to OPCs cultured on a control substrate. OPCs in contact with myelin stopped proliferating and decreased the expression of OPC markers to a comparable degree as cells grown on a control substrate. The expression of two transcription factors known to prevent OPC differentiation and maturation were increased in cells that were in contact with myelin: inhibitor of differentiation family (ID) members 2 and 4. Overexpression of ID2 and ID4 in OPCs was previously reported to decrease the percentage of cells expressing mature oligodendrocyte markers. However, knockdown of ID2 and/or ID4 in OPCs did not increase oligodendroglial maturation on or off of myelin, suggesting that contact with myelin regulates additional regulatory elements.

Citing Articles

Targeting Remyelination in Spinal Cord Injury: Insights and Emerging Therapeutic Strategies.

Al Mamun A, Quan Z, Geng P, Wang S, Shao C, Xiao J CNS Neurosci Ther. 2024; 30(12):1-15.

PMID: 39723448 PMC: 11669846. DOI: 10.1111/cns.70193.


Should We Consider Neurodegeneration by Itself or in a Triangulation with Neuroinflammation and Demyelination? The Example of Multiple Sclerosis and Beyond.

Perdaens O, van Pesch V Int J Mol Sci. 2024; 25(23.

PMID: 39684351 PMC: 11641818. DOI: 10.3390/ijms252312637.


Glial Cells as Key Regulators in Neuroinflammatory Mechanisms Associated with Multiple Sclerosis.

Theophanous S, Sargiannidou I, Kleopa K Int J Mol Sci. 2024; 25(17).

PMID: 39273535 PMC: 11395575. DOI: 10.3390/ijms25179588.


Microglia and Multiple Sclerosis.

Hammond B, Panda S, Kaushik D, Plemel J Adv Neurobiol. 2024; 37:445-456.

PMID: 39207707 DOI: 10.1007/978-3-031-55529-9_25.


Differential Expression of PACAP/VIP Receptors in the Post-Mortem CNS White Matter of Multiple Sclerosis Donors.

Jansen M, Musumeci G, Castorina A Int J Mol Sci. 2024; 25(16).

PMID: 39201536 PMC: 11354662. DOI: 10.3390/ijms25168850.